BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35020071)

  • 41. NR4A1 Regulates Tamoxifen Resistance by Suppressing ERK Signaling in ER-Positive Breast Cancer.
    Kim YC; Kim CY; Oh JH; Kim MH
    Cells; 2021 Jun; 10(7):. PubMed ID: 34209871
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
    Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Transcriptomic signature predicts the distant relapse in patients with ER+ breast cancer treated with tamoxifen for five years.
    Zhou H; Lv Q; Guo Z
    Mol Med Rep; 2018 Feb; 17(2):3152-3157. PubMed ID: 29257261
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
    Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
    Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer.
    Meijer D; Sieuwerts AM; Look MP; van Agthoven T; Foekens JA; Dorssers LC
    Endocr Relat Cancer; 2008 Mar; 15(1):101-11. PubMed ID: 18310279
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.
    Ahern TP; Cronin-Fenton DP; Lash TL; Sørensen HT; Ording AG; Hamilton-Dutoit SJ; Hellberg Y
    Acta Oncol; 2016 Jun; 55(6):734-41. PubMed ID: 27056567
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
    Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
    J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98.
    Alkner S; Jensen MB; Rasmussen BB; Bendahl PO; Fernö M; Rydén L; Mouridsen H;
    Breast Cancer Res Treat; 2017 Nov; 166(2):481-490. PubMed ID: 28766132
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance.
    Busch S; Sims AH; Stål O; Fernö M; Landberg G
    Cancer Res; 2015 Apr; 75(7):1457-69. PubMed ID: 25833830
    [TBL] [Abstract][Full Text] [Related]  

  • 50. IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer.
    Kruger DT; Alexi X; Opdam M; Schuurman K; Voorwerk L; Sanders J; van der Noort V; Boven E; Zwart W; Linn SC
    Int J Cancer; 2020 Apr; 146(8):2348-2359. PubMed ID: 31490549
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients.
    Knoop AS; Bentzen SM; Nielsen MM; Rasmussen BB; Rose C
    J Clin Oncol; 2001 Jul; 19(14):3376-84. PubMed ID: 11454885
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.
    Johnston SR; Saccani-Jotti G; Smith IE; Salter J; Newby J; Coppen M; Ebbs SR; Dowsett M
    Cancer Res; 1995 Aug; 55(15):3331-8. PubMed ID: 7614468
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.
    Dowsett M; Houghton J; Iden C; Salter J; Farndon J; A'Hern R; Sainsbury R; Baum M
    Ann Oncol; 2006 May; 17(5):818-26. PubMed ID: 16497822
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer.
    Zhang H; Wang J; Li J; Zhou X; Yin L; Wang Y; Gu Y; Niu X; Yang Y; Ji H; Zhang Q
    Cancer Sci; 2021 Apr; 112(4):1603-1613. PubMed ID: 33453094
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CIP2A expression predicts recurrences of tamoxifen-treated breast cancer.
    Baldacchino S; Wastall LM; Saliba C; Hughes TA; Scerri C; Berwick A; Speirs V; Hanby AM; Grech G
    Tumour Biol; 2017 Oct; 39(10):1010428317722064. PubMed ID: 29034804
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo.
    Cheng S; Castillo V; Welty M; Alvarado M; Eliaz I; Temm CJ; Sandusky GE; Sliva D
    BMC Complement Altern Med; 2017 Feb; 17(1):115. PubMed ID: 28209156
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High IKKα expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)-positive breast cancer.
    Bennett L; Quinn J; McCall P; Mallon EA; Horgan PG; McMillan DC; Paul A; Edwards J
    Int J Cancer; 2017 Apr; 140(7):1633-1644. PubMed ID: 28006839
    [TBL] [Abstract][Full Text] [Related]  

  • 59. GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.
    Liu J; Prager-van der Smissen WJ; Look MP; Sieuwerts AM; Smid M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
    Cancer Lett; 2016 Jun; 376(1):104-9. PubMed ID: 27018307
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy.
    Bartlett JM; Thomas J; Ross DT; Seitz RS; Ring BZ; Beck RA; Pedersen HC; Munro A; Kunkler IH; Campbell FM; Jack W; Kerr GR; Johnstone L; Cameron DA; Chetty U
    Breast Cancer Res; 2010; 12(4):R47. PubMed ID: 20615243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.